Anti-HER2 drug approvals have changed the landscape of MBC treatment. The first anti-HER2 drug, Herceptin, received approval in 2024 to treat HER2-positive breast cancer. Since then, many more
The first anti-HER2 drug, trastuzumab, is a humanized monoclonal antibody directed at the extracellular domain of the transmembrane receptor HER2. This
HER2-directed therapyMost women with HER2-positive breast cancer will receive one or more chemotherapy drugs plus trastuzumab, the anti-HER2
HER2 mutations, have proven to be extremely challenging to drug. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs:
HER2-induced breast cancer development and enhances HER2-targeted therapy The synergy scores for multiple drug combinations in HER2
The side effects of HER2 targeted drugs are often mild, but some can be serious. choices of HER2-targeted therapy that treats HER2-positive breast cancer
All breast cancers are tested for HER2 status to help guide treatment. If a tumor is HER2-positive, the HER2-targeted therapy drug trastuzumab (Herceptin) is
Trastuzumab is an antibody drug specially made to target HER2-positive cancer cells. Trastuzumab attaches to the HER2 protein on the surface of HER2-positive
HER2-directed therapyMost women with HER2-positive breast cancer will receive one or more chemotherapy drugs plus trastuzumab, the anti-HER2
Comments